Compounds > sodium phytate
Page last updated: 2024-11-06

sodium phytate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

SNF472: the hexasodium salt of phytate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID91667962
MeSH IDM0016821

Synonyms (21)

Synonym
(1r,2r,3s,4s,5r,6s)-cyclohexane-1,2,3,4,5,6-hexayl-hexakis(dihydrogen phosphate)
hexasodium fytate [inn]
snf472
snf-472
hexasodium fytate
inositol, hexakis(dihydrogen phosphate) hexasodium salt, myo-
hexasodium phytate
34367-89-0
zbx50ug81v ,
myo-inositol, hexakis(dihydrogen phosphate), hexasodium salt
unii-zbx50ug81v
34367-89-0(hexasodium phytate)
scyllo-inositol,1,2,3,4,5,6-hexakis(dihydrogenphosphate),hexasodiumsalt
(1r,2r,3s,4s,5s,6s)-cyclohexane-(1,2,3,4,5,6)-hexaylhexakis(hydrogenphosphate),hexasodiumsalt
sodium cyclohexane-1,2,3,4,5,6-hexayl hexakis(hydrogen phosphate)
Q27295268
hexasodium;[2,3,4,5,6-pentakis[[hydroxy(oxido)phosphoryl]oxy]cyclohexyl] hydrogen phosphate
DTXSID001021738
PD064201
PD064210
PD094362

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"SNF472 is safe and well tolerated in HD patients after 2 schemes: multiple ascending doses for 1 week and after repeated dosing of 10 mg/kg for 4 weeks."( A phase 1b randomized, placebo-controlled clinical trial with SNF472 in haemodialysis patients.
Campistol, JM; Canals, AZ; Ferrer, MD; Joubert, PH; Maduell, F; Ojeda, R; Perelló, J; Salcedo, C; Torregrosa, V, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (40.00)24.3611
2020's6 (60.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (45.45%)5.53%
Reviews1 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (45.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phytic acid
Phytic Acid: Complexing agent for removal of traces of heavy metal ions. It acts also as a hypocalcemic agent.. myo-inositol hexakisphosphate : A myo-inositol hexakisphosphate in which each hydroxy group of myo-inositol is monophosphorylated.		9.19105inositol phosphate
durapatite
Durapatite: The mineral component of bones and teeth; it has been used therapeutically as a prosthetic aid and in the prevention and treatment of osteoporosis.. hydroxylapatite : A phosphate mineral with the formula Ca5(PO4)3(OH).		5.522
tricalcium phosphate
tricalcium phosphate: a form of tricalcium phosphate used as bioceramic bone replacement material; see also records for alpha-tricalcium phosphate, beta-tricalcium phosphate, calcium phosphate; apatitic tricalcium phosphate Ca9(HPO4)(PO4)5(OH) is the calcium orthophosphate leading to beta tricalcium phosphate Ca3(PO4)2 (b-TCP). calcium phosphate : A calcium salt composed of calcium and phosphate/diphosphate ions; present in milk and used for the mineralisation of calcified tissues.		2.2510calcium phosphate
ConditionIndicatedRelationship StrengthStudiesTrials
Calciphylaxes
[description not available]		04.3131
Ache
[description not available]		03.5911
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		03.5911
Disease Exacerbation
[description not available]		04.9621
Vascular Calcification
Deposition of calcium into the blood vessel structures. Excessive calcification of the vessels are associated with ATHEROSCLEROTIC PLAQUES formation particularly after MYOCARDIAL INFARCTION (see MONCKEBERG MEDIAL CALCIFIC SCLEROSIS) and chronic kidney diseases which in turn increase VASCULAR STIFFNESS.		07.2662
Arteriosclerosis, Coronary
[description not available]		04.5511
Heart Valve Diseases
Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).		04.5511
Chronic Kidney Failure
[description not available]		07.2843
Coronary Artery Disease
Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.		04.5511
Kidney Failure, Chronic
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.		07.2843
Chronic Kidney Diseases
[description not available]		02.2510
Renal Insufficiency, Chronic
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)		02.2510
Calcification, Pathologic
[description not available]		04.0221
Calcinosis
Pathologic deposition of calcium salts in tissues.		04.0221
Cardiomyopathies, Primary
[description not available]		03.5911
Cardiomyopathies
A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).		03.5911